Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS)
CNY118.15
+0.54 (+0.46%)
CN SHH Healthcare Biotechnology
Address
No. 268 Lingxiaohua Road
Shanghai, CN
Shanghai, CN
CEO
Jinhao Du
Website
allist.com.cn
IPO
2020-12-02
ISIN CNE100005XJ7
Description
Established in 2004, Shanghai Allist Pharmaceuticals Co., Ltd. is a Chinese enterprise dedicated to the innovation and development of medicinal products. Headquartered in Shanghai, the company focuses its efforts on creating therapeutic agents specifically for the treatment of various tumor and cancer-related conditions.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY118.15
+0.54 (+0.46%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.14
Float Shares
184.45M
Free Float %
41.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.95% | -2.57% | -3.11% | -3.23% | -8.72% | -13.86% | -8.45% | +221.00% | +179.59% | +132.74% | +132.74% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
118.15
DCF (Unlevered)
526.59
+345.7%
DCF (Levered)
248.74
+110.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
31.00
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✓ MOAT relativo
-
Revenue growth Biotechnology: +1.6%+45.4% ★ Q1'26: +44.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+52.5% ★ Q1'26: +54.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+42.9% ★ Q1'26: +35.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+48.9% ★ Q1'26: +45.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+61.6% ★ Q1'26: +53.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
560.9K
est: 520.0K (+7.9%)
|
530.09M
est: 614.00M (-13.7%)
|
791.00M
est: 782.58M (+1.1%)
|
2.02B
est: 2.01B (+0.3%)
|
3.56B
est: 3.55B (+0.2%)
|
5.17B
est: 5.11B (+1.2%)
|
6.72B
6.71B – 6.73B
+31.6% YoY
|
7.90B
7.22B – 8.28B
+17.5% YoY
|
9.00B
8.60B – 9.41B
+14.0% YoY
|
9.09B
8.66B – 9.32B
+0.9% YoY
|
| EBITDA |
-297.46M
est: -32.8K (-905,681.9%)
|
32.69M
est: -38.78M (+184.3%)
|
146.49M
est: -49.42M (+396.4%)
|
693.37M
est: -127.07M (+645.7%)
|
1.65B
est: 1.10B (+50.1%)
|
2.57B
est: 1.59B (+61.9%)
|
2.09B
2.08B – 2.09B
+31.6% YoY
|
2.45B
2.24B – 2.57B
+17.5% YoY
|
2.79B
2.67B – 2.92B
+14.0% YoY
|
2.82B
2.69B – 2.89B
+0.9% YoY
|
| EBIT |
-309.32M
est: -41.2K (-751,320.7%)
|
18.88M
est: -48.61M (+138.8%)
|
126.32M
est: -61.95M (+303.9%)
|
656.43M
est: -159.28M (+512.1%)
|
1.62B
est: 1.04B (+55.5%)
|
2.53B
est: 1.50B (+69.1%)
|
1.97B
1.97B – 1.97B
+31.6% YoY
|
2.31B
2.11B – 2.42B
+17.5% YoY
|
2.64B
2.52B – 2.76B
+14.0% YoY
|
2.66B
2.54B – 2.73B
+0.9% YoY
|
| Net Income |
-310.52M
est: -305.75M (-1.6%)
|
18.27M
est: 103.42M (-82.3%)
|
130.52M
est: 74.19M (+75.9%)
|
644.17M
est: 642.98M (+0.2%)
|
1.43B
est: 1.39B (+2.6%)
|
2.18B
est: 1.94B (+12.3%)
|
2.65B
2.63B – 2.66B
+36.3% YoY
|
2.92B
2.74B – 3.36B
+10.4% YoY
|
3.71B
3.59B – 3.77B
+26.9% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
179.46M
est: 12.11M (+1,381.7%)
|
366.44M
est: 14.30B (-97.4%)
|
524.11M
est: 18.23B (-97.1%)
|
1.05B
est: 46.86B (-97.8%)
|
1.58B
est: 1.65B (-4.2%)
|
—
est: 2.37B (-100.0%)
|
3.12B
3.11B – 3.12B
+31.6% YoY
|
3.66B
3.35B – 3.84B
+17.5% YoY
|
4.18B
3.99B – 4.36B
+14.0% YoY
|
4.21B
4.02B – 4.32B
+0.9% YoY
|
| EPS |
-0.84
est: -0.68 (-23.5%)
|
0.04
est: 0.23 (-82.6%)
|
0.29
est: 0.17 (+75.8%)
|
1.43
est: 1.43 (+0.0%)
|
3.18
est: 3.14 (+1.3%)
|
4.85
est: 4.38 (+10.7%)
|
5.88
5.85 – 5.91
+34.2% YoY
|
6.98
6.09 – 7.46
+18.7% YoY
|
8.19
7.99 – 8.39
+17.4% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 1/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 1/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 1/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 1/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 1/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 1/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-15 | B | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.56B
OE per share TTM
3.47
Owner's Yield
3.87%
Maintenance CapEx ratio
13.42%
Maint CapEx / Avg PPE
19.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
2.42M
Shares Outstanding
450.00M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen Huang | Marketing Manager | — | male |
| Feng Xu | Director & Deputy GM | — | male |
| Huafeng Shan | Chief Quality Officer | — | female |
| Huayong Zhou | Deputy Director of R&D | — | male |
| Huibing Luo | Chief Chemistry Officer | — | male |
| Jie Hu | Vice Chairman & Deputy GM | — | male |
| Jinhao Du | Chairman of the Board & GM | — | male |
| Lin Wang | Financial Director | — | male |
| Quan Gan | Accounting Supervisor | — | — |
| Shuo Li | Board Secretary | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688578.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
